A retrospective study evaluating effect of natural history of melanoma on response rate in advanced melanoma patients treated with nivolumab and pembrolizumab.

Trial Profile

A retrospective study evaluating effect of natural history of melanoma on response rate in advanced melanoma patients treated with nivolumab and pembrolizumab.

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Dec 2016 New trial record
    • 11 Oct 2016 Results assessing correlation between natural history of melanoma and response rate presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top